Study of serum procalcitonin and lactate levels in women with preeclampsia


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Objective: Assessment of serum procalcitonin (PCT) and lactate levels and analysis of the prevalence of polymorphic variants of thrombophilia and folate cycle genes in pregnant women with preeclampsia (PE). Materials and methods: The study included 40 pregnant women with PE and 40 women with normal pregnancy in the control group. Along with standard clinical and biochemical tests, in all pregnant women serum PCT and lactate levels were measured, as well as genetic analysis of genes polymorphisms associated with thrombophilia: F2 (rs1799963, G20210A), F5 (rs6025, G1691A) and MTHFR (rs1801133, C677T) was performed. Results: A significant increase in both standard clinical and biochemical parameters, and PCT and lactate levels was found in pregnant women with PE compared to the control group. The study also showed, that the development of severe PE was not associated with elevated serum PCTand lactate levels. There were no statistically significant differences between the studied groups in the prevalence of the studied polymorphisms in F2, F5 and MTHFR genes. It was found that the level of PCT in the group of women with PE with genotype 1 or 2 of T-allele of MTHFR gene C677T polymorph ism (CT and TT genotypes) was lower than in the group of women with PE with CC genotype. Conclusion: The results of the study showed that PCT and lactate tests in combination with standard clinical and laboratory parameters have clinical value in the early diagnosis of PE. However, the use of PCT and lactate combination as a marker for clarifying the disease severity is limited. The influence of polymorphisms in F2, F5, MTHFR genes on the development of PE in the studied groups was not confirmed.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Авторлар туралы

Ksenia Semashchenko

Siberian Federal University

Email: kseniya.semashchenko@mam.ru
Postgraduate Student, the 1st course

Ekaterina Vasilyeva

Siberian Federal University; City Maternity Hospital No. 5, Krasnoyarsk

Postgraduate Student, the 2nd course

Natalia Molokova

City Maternity Hospital No. 5, Krasnoyarsk

Email: nataacadem@mail.ru
PhD (Bio), Biologist of Clinical Laboratory Diagnostics

Olga Zhitkova

City Maternity Hospital No. 5, Krasnoyarsk

Email: zhitkoval973@list.ru
Head of Clinical Laboratory Diagnostics

Tatyana Subbotina

Siberian Federal University; Federal Siberian Research and Clinical Center of the Federal Medical and Biological Agency of Russia

Email: stn.25@mail.ru
PhD (Bio), Associate Professor at the Department of Medical Biology, Head of the Scientific and Practical Laboratory for Molecular Genetic Research Methods

Әдебиет тізімі

  1. Адамян Л.В., Артымук Н.В., Башмакова Н.В., Белокриницкая Т.Е., Беломестное С.Р., Братищев И.В., Вученович Ю.Д., Краснопольский В.И., Куликов А.В., Левит А.Л., Никитина Н.А., Петрухин В.А., Пырегов А.В., Серов В.Н., Сидорова И.С., Филиппов О. С., Ходжаева З.С., Холин А.М., Шешко Е.Л., Шифман Е.М., Шмаков Р.Г. Гипертензивные расстройства во время беременности, в родах и послеродовом периоде. Преэклампсия. Эклампсия. Клинические рекомендации (протокол лечения). М.; 2016. 40c.
  2. Головченко О.В. Молекулярно-генетические детерминанты преэклам-псии. Научные результаты биомедицинских исследований. 2019; 5(4): 139-49. https://dx.doi.org/10.18413/2658-6533-2019-5-4-0-11.
  3. Jannesari R., Kazemi E. Level of high sensitive C-reactive protein and procalcitonin in pregnant women with mild and severe preeclampsia. Adv. Biomed. Res. 2017; 6: 140. https://dx.doi.org/10.4103/2277-9175.218032.
  4. Mangogna A., Agostinis C., Ricci G., Romano F., Bulla R. Overview of procalcitonin in pregnancy and in pre-eclampsia. Clin. Exp. Immunol. 2019; 198(1): 37-46. https://dx.doi.org/10.1111/cei.13311.
  5. Vijayan A.L., Vanimaya, Ravindran S., Saikant R., Lakshmi S., Kartik R. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. J. Intensive Care. 2017; 5: 51. https://dx.doi.org/10.1186/s40560-017-0246-8.
  6. Садыкова Г.К. Оптимизация прогностического алгоритма в диагностике тяжелого гестоза. Пермский медицинский журнал. 2008; 25(3): 44-7.
  7. Agostinis C., Rami D., Zacchi P., Bossi F., Stampalija T., Mangogna A. et al. Preeclampsia affects procalcitonin production in placental tissue. Am. J. Reprod. Immunol. 2018; 79(4): e12823. https://dx.doi.org/10.1111/aji.12823.
  8. Peguero A., Parra R.A., Carrillo S.P., Rjas-Suarez J., Figuras F. Association of plasma lactate concentration at admission of severe preeclampsia to maternal complications. Pregnancy Hypertens. 2019; 17: 89-93. https://dx.doi.org/10.1016/j.preghy.2019.05.003.
  9. Бен Амор Мариам, Гнатко Е.П., Турос Е.И., Брезицкая Н.В. Анализ показателей системы гемостаза при преэклампсии различной степени тяжести. ScienceRise: Medical Science. 2016; 8(4): 10-5.
  10. Гнатко Е.П., Турос Е.И., Брезицкая Н.В., Бен Амор Мариам, Сидоренко Е.А. Молекулярно-генетическое исследование полиморфизма генов фолатного обмена и гемостаза при преэклампсии. Охрана материнства и детства. 2014; 2: 52-5.
  11. Fong F.M., Sahemey M.K., Hamedi G., Eyitayo R., Yates D., Kuan V. et al. Maternal genotype and severe preeclampsia: a HuGE review. Am. J. Epidemiol. 2014; 180(4): 335-45. https://dx.doi.org/10.1093/aje/kwu151.
  12. Wang X., Bai T., Liu S., Pan H., Wang B. Association between thrombophilia gene polymorphisms and preeclampsia: a meta analysis. PloS One. 2014; 9(6): e100789. https://dx.doi.org/10.1371/journal.pone.0100789.
  13. Макацария А.Д., Бицадзе В.О., Хизроева Д.Х. HELLP-синдром. Акушерство, гинекология и репродукция. 2014; 8(2): 61-8.
  14. Медведев Б.И., Сюндюкова Е.Г., Сашенков С.Л. Клинико-биохимические предикторы развития преэклампсии. Акушерство и гинекология. 2013; 5: 30-5.
  15. Башмакова Н.В., Цывьян П.Б., Чистякова Г.Н., Пестряева Л.А. Гагарина Е.М., Петрова М.М. Ангиогенные ростовые факторы и патогенез преэклампсии. Российский вестник акушера-гинеколога. 2017; 17(5): 7-12. https://dx.doi.org/10.17116/rosakush20171757-12.
  16. Guida J.P., Parpinelli M.A., Surita F.G., Costa M.L. The impact of proteinuria on maternal and perinatal outcomes among women with pre-eclampsia. Int. J. Gynaecol. Obstet. 2018; 143(1): 101-7. https://dx.doi.org/10.1002/ijgo.12487.
  17. Tanacan A., Fadiloglu E., Beksac M.S. The importance of proteinuria in preeclampsia and its predictive role in maternal and neonatal outcomes. Hypertens. Pregnancy. 2019; 38(2): 111-8. https://dx.doi.org/10.1080/10641955.2019.1590718.
  18. Лоскутова Т.А. Анализ форм тромбофилии у беременных с акушерскими и перинатальными осложнениями при преэклампсии. Акушерство и гинекология. 2013; 10: 23-7.
  19. Ahmed S.F., Ali M.M., Kheiri S., Elzaki S.E.G., Adam I. Association of methylenetetrahydrofolate reductase C677T and reduced-f carrier-1 G80A gene polymorphism with preeclampsia in Sudanese women. Hypertens. Pregnancy. 2020; 39(2): 77-81. https://dx.doi.org/10.1080/10641955.2020.1725037.
  20. Jaaskelainen E., Keski-Nisula L., Toivonen S., Romppanen E-L., Helisalmi S., Punnonen K. et al. MTHFR C677T polymorphism is not associated with placental abruption or preeclampsia in Finnish women. Hypertens. Pregnancy. 2006; 25(2): 73-80. https://dx.doi.org/10.1080/10641950600745137.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2021

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>